OptiBiotix Health (OPTI) AI Stock Analysis

• Market Cap: £7.49M
• Dividend Yield: N/A
• Average Volume (3M): 268.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 103,300,300
• 10 Day Avg. Volume: 266,472
• 30 Day Avg. Volume: 268,800
• PEG Ratio: 0.53
• Price to Book (P/B): 2.10
• Price to Sales (P/S): 20.26
• P/FCF Ratio: -9.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 7.50p ▲(11.11% Upside)

The score is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.

Positive Factors

Debt-free balance sheet

A zero-debt, net-cash-like balance sheet provides lasting financial flexibility: it lowers insolvency risk, supports continued R&D and partner investments, and increases options for non-dilutive deals or selective M&A over the next several quarters if cash burn is managed.

Accelerating revenue growth

Sustained double-digit revenue acceleration signals improving commercial traction with partners and end markets. Durable top-line momentum supports scaling gross profit and negotiation leverage in B2B deals, helping a path toward margin improvement if unit economics hold.

B2B, partner-led business model

A partner-centric revenue model (ingredient sales, licensing, milestones, distribution) reduces consumer go-to-market costs, leverages partners' scale, and creates multiple recurring revenue streams; structurally supports scalable growth without large direct sales overhead.

Negative Factors

Persistent negative cash flow

Consistent operating and free cash outflows create an ongoing funding requirement. Over a multi-quarter horizon this raises dilution or refinancing risk, constrains marketing and development investments, and limits the company’s ability to self-fund commercial expansion.

Deep net losses and weak margins

Very negative net margins indicate current economics are unsustainable without structural change. Large losses reduce retained earnings, pressure investor tolerance for further investment, and make profitability highly contingent on either rapid revenue scale or materially improved gross-to-operating margin conversion.

Very limited internal resources

A tiny headcount constrains internal R&D, regulatory, and commercial bandwidth, increasing reliance on partners for execution. Over months, limited personnel can slow product development, regulatory progress and partner management, elevating execution risk as revenues must scale.

OptiBiotix Health Business Overview & Revenue Model

Company Description

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.

How the Company Makes Money

OptiBiotix Health Financial Statement Overview

Summary

Revenue growth accelerated in 2024 (+52.9% YoY), but profitability remains very weak with large net losses relative to revenue and continued negative cash flow/free cash flow. The balance sheet is a key offset (no debt, sizable equity), but ongoing losses and cash burn keep the overall financial profile below average.

Income Statement

Revenue growth accelerated in 2024 (+52.9% YoY), showing improving commercial traction. However, profitability remains weak: despite positive gross margin (~38% in 2024), the company is still deeply loss-making with very large operating and net losses relative to revenue (2024 net margin about -207%), and margins deteriorated versus the unusually strong profit levels reported in 2020–2022. Overall, growth is encouraging, but the earnings profile is not yet sustainable.

Balance Sheet

The balance sheet is a clear strength, with zero total debt in 2023–2024 and a net-cash-like posture implied by no leverage. Equity remains sizable (2024 stockholders’ equity ~8.4m vs. assets ~9.0m), providing financial flexibility. The main weakness is persistently negative returns in the last two years (2023–2024), indicating the capital base is not currently generating profits.

Cash Flow

Cash generation is a major pressure point: operating cash flow and free cash flow are consistently negative across the period, including 2024 (both about -1.77m). Cash burn worsened in absolute terms from 2023 to 2024, and cash flow does not yet reflect a self-funding model. While free cash flow moved modestly year-to-year in places, the overall pattern is continued outflows that likely require ongoing funding support.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.15M	870.00K	644.00K	457.00K	2.21M	1.52M
Gross Profit	420.00K	331.00K	320.00K	244.00K	1.12M	879.82K
EBITDA	-67.00K	-2.06M	-1.84M	2.75M	6.51M	6.31M
Net Income	-191.00K	-1.80M	-2.04M	2.59M	6.26M	5.80M
Balance Sheet
Total Assets	9.15M	9.04M	9.40M	11.55M	20.14M	13.70M
Cash, Cash Equivalents and Short-Term Investments	1.30M	739.00K	635.00K	1.05M	2.01M	864.68K
Total Debt	0.00	0.00	0.00	0.00	819.36K	771.76K
Total Liabilities	732.00K	647.00K	532.00K	643.00K	1.97M	1.85M
Stockholders Equity	8.42M	8.40M	8.87M	10.90M	18.14M	11.82M
Cash Flow
Free Cash Flow	-1.92M	-1.77M	-1.53M	-1.28M	-1.76M	-1.28M
Operating Cash Flow	-1.92M	-1.77M	-1.53M	-1.11M	-1.56M	-927.96K
Investing Cash Flow	1.24M	587.00K	1.11M	-331.00K	-193.51K	-350.35K
Financing Cash Flow	714.00K	1.28M	0.00	485.00K	2.90M	1.69M

OptiBiotix Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.67M	-0.64	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SBTX	50 Neutral	£53.08M	-62.12	-11.24%	―	283.74%	78.57%
NFX	46 Neutral	£4.01M	-4.75	-153.80%	―	―	-616.67%
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
OPTI	43 Neutral	£7.49M	-51.79	-2.42%	―	―	―
CIZ	43 Neutral	£5.55M	-5.00	-433.59%	―	―	―

OptiBiotix Health Corporate Events

OptiBiotix Secures Record Early 2026 Orders as SlimBiome Demand Surges

OptiBiotix Health has secured four significant orders totalling 24 metric tonnes of its flagship weight management ingredient SlimBiome from Taiwanese distributor Meelung Trading, to be delivered in staged shipments throughout 2026, reflecting rapid sales growth since their agreement in mid-2025. Together with a previously announced low six-figure order from a major weight management company and commitments from two other partners, the group has locked in more than £800,000 of non-cancellable orders early in the year, giving it improved visibility, supply-chain efficiencies and pricing leverage as it targets the rapidly expanding “natural alternative to GLP-1” market, where SlimBiome’s clinical backing and regulatory claims position the company for further growth and a stronger competitive footing going into 2026.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

OptiBiotix Launches Interactive Investor Hub to Deepen Shareholder Engagement

OptiBiotix Health has launched an interactive investor website that consolidates its corporate, commercial and research content into a single digital hub aimed at improving transparency and engagement with current and prospective shareholders. The platform hosts regulatory announcements, financial reports, presentations, research overviews and partner interviews, while also enabling investors to submit questions directly to management for timely responses, a move the company says will provide richer context on commercial progress and product development—particularly around second-generation offerings like SweetBiotix®—and strengthen its communication strategy as it pursues growth in the microbiome health sector.

The most recent analyst rating on (GB:OPTI) stock is a Hold with a £6.50 price target. To see the full list of analyst forecasts on OptiBiotix Health stock, see the GB:OPTI Stock Forecast page.

OptiBiotix Health Enhances SweetBiotix Production with New Enzymatic Process

OptiBiotix Health has announced significant advancements in the production of its SweetBiotix® product line, which consists of natural, high-fiber, low-calorie sweeteners designed to replace sugar and artificial substitutes. The company has developed a new enzymatic process that increases yield and purity, reduces production costs, and enhances the taste profile of SweetBiotix products. This innovation not only strengthens OptiBiotix’s market position by addressing health concerns associated with sugar substitutes but also opens up new partnership opportunities with sugar producers. The breakthrough is expected to boost investor confidence and expand the commercial potential of SweetBiotix products.

OptiBiotix Secures First Major Order with European Weight Management Firm

OptiBiotix Health has announced its first order from a well-known weight management company for its SlimBiome® and WellBiome® products, marking a significant step in its strategy to provide private label products. This order highlights the growing interest in natural alternatives to GLP1 in the weight management market, which is projected to grow significantly in the coming years. The company’s collaboration with international brands like Hydroxycut and LightLife further strengthens its position in the industry, potentially boosting future sales and shareholder value.